Hatchtech Pty Ltd. is the developer of a proprietary next generation head lice treatment, DeOvo™, which has successfully completed two pivotal Phase 3 clinical studies. The company plans to file a New Drug Application with the Food and Drug Administration (FDA) in the United States in the first half of 2015.

DeOvo™, recently renamed as Xeglyze™ Lotion, is a head lice product in development that has been studied in clinical trials to evaluate its effect on all lifecycle stages of the organism in a single application.

Xeglyze™ is a topical lotion containing an inhibitor of metal dependent targets that are involved in all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established its mode of action, and preclinical and clinical studies have evaluated the efficacy and safety of Xeglyze™.

Hatchtech is securely financed by a consortium of specialist venture capitalists and is located in Melbourne, Australia.

Latest News

Oct 21, 2014 Hatchtech Announces Successful Results from Phase 2 Ovicidal Study

Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results

Dec 11, 2013 Hatchtech Receives SPA and Announces Patent Grants

Oct 31, 2013 Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission